This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunology  • Immunologic Disorders  • Alert me on articles by topic

A Time for Reassessment

Arch Ophthalmol. 1999;117(11):1549-1550.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE NEW ENGLAND JOURNAL OF MEDICINE

Oral Ganciclovir for Patients With Cytomegalovirus Retinitis Treated With a Ganciclovir Implant

Daniel F. Martin, MD; Baruch D. Kuppermann, MD, PhD; Richard A. Wolitz, MD; Alan G. Palestine, MD; Hong Li, MS; Charles A. Robinson, MD; and the Roche Ganciclovir Study Group

Background  The intraocular ganciclovir implant is effective for local treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does not treat or prevent other systemic manifestations of cytomegalovirus infection.

Methods  Three hundred seventy-seven patients with AIDS and unilateral cytomegalovirus retinitis were randomly assigned to 1 of 3 treatments: a ganciclovir implant plus oral ganciclovir (4.5 g daily), a ganciclovir implant plus oral placebo, or intravenous ganciclovir alone. The primary outcome measure was the development of new cytomegalovirus disease, either contralateral retinitis or biopsy-proved extraocular disease.

Results  The incidence of new cytomegalovirus disease at 6 months was 44.3% . . . [Full Text of this Article]